MedTrace Logo

Effect of Vascular Endothelial Growth Factor Blockers on Aqueous Humor Dynamics

NCT01994174 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 13

Last updated 2023-10-06

No results posted yet for this study

Summary

The objective of this research is to determine the effects of anti-VEGF drugs (bevacizumab, ranibizumab or aflibercept) on aqueous humor dynamics (AHD) in patients with retinal vascular disease. The underlying hypothesis is that anti-VEGF drugs increase intraocular pressure (IOP) by increasing aqueous inflow, decreasing uveoscleral outflow or both. The specific aim is to evaluate the changes produced in AHD after 1 baseline and a subsequent 1 monthly injection of anti VEGF agents.

Conditions

  • Macular Disease

Sponsors & Collaborators

  • University of Nebraska

    lead OTHER

Principal Investigators

  • Vikas Gulati, MD · University of Nebraska

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-20
Primary Completion
2023-01-12
Completion
2023-01-12

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01994174 on ClinicalTrials.gov